Active Biotech's nominations committee appointed


The nominations committee for the next Board election consists of Johnny Sommarlund for MGA Holding, Viveca Ax:son Johnson for Nordstjernan and Ulf Strömsten for Catella Fonder.
Headed by the Chairman of the board, Mats Arnhög, the nominations committee will prepare a proposal for the composition of the Board to be presented to the Annual General Meeting on April 21, 2005.
Lund, December 20, 2004
Active Biotech AB (publ)
Sven Andréasson
President and CEO
Active Biotech AB is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong research portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects involve unique substances with immunomodulatory properties (SAIK-MS) intended for the treatment of diseases including multiple sclerosis, as well as a novel concept for the treatment of cancer (TTS).
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50